Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease, but the role of mutation ...

Opens in a new tab or window Clearance of driver mutations at day 30 after transplantation was associated with a reduced risk of relapse and better survival among patients with myelofibrosis ...

People living with this rare blood cancer often deal with complex and unpredictable symptoms. Connecting with support and ...

Patients with myelofibrosis who cleared their mutations 30 days following stem cell transplantation experienced fewer relapses. They also achieved longer DFS and OS. Patients with myelofibrosis ...

However, in about half of the cases of primary myelofibrosis, a mutation in the JAK2 gene is found. The JAK2 mutation is also frequently found in those with polycythemia vera and essential ...

Myelofibrosis is a rare cancer that affects your bone marrow, the spongy tissue inside some of your bones. In a healthy person, stem cells in the bone marrow make the red blood cells, white blood ...

Turro at University of Cambridge in Cambridge, UK, and colleagues was titled, 'A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis ...

is being evaluated in a Phase 1/2 study in patients with relapsed/refractory myelofibrosis Enzomenib (DSP-5336), an investigational, oral small molecule designed to inhibit the menin and KMT2A ...